Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 2Leukemia, Lymphocytic, Chronic, B-Cell 2Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm Metastasis 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 42Cytarabine 25fludarabine phosphate 24Dexamethasone 23Methotrexate 22fludarabine 21Peripheral Blood Stem Cell Transplantation 21Vincristine 16Filgrastim 16venetoclax 14Etoposide 13Rituximab 12Mycophenolic Acid 12Whole-Body Irradiation 11Cyclosporine 10Clofarabine 10Calcium Dobesilate 10blinatumomab 9Tacrolimus 9pegaspargase 8Busulfan 8Bortezomib 8Alemtuzumab 8Mitoxantrone 7Melphalan 7Leucovorin 7Immunotherapy, Adoptive 7nilotinib 6Mesna 6Mercaptopurine 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Precursor Cell Lymphoblastic Leukemia-Lymphoma × idelalisib × Clear all
NCT03742323 2021-09-05

REALIB-LLA-2017: Idelalisib in Patients With Acute Lymphoblastic Leukemia

PETHEMA Foundation

Phase 1/2 Terminated
6 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡